Stockreport

UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF Collaboration will focus on UGN-302 as an investigational treatment for high-grade non-muscle invasive bladder cancer PRINCETON, N.J. & HOUSTON--(BUSINESS WIRE)--UroG [Read more]